Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and stratification according to CEC count

	CEC at baseline					CEC at 2 mo
	11/μL or less	More than 11/μL	P	11/μL or less	More than 11/μL	P
No. entered or eligible	42	62		44	37
Median age, y (range)	54 (32-78)	54 (34-78)	.71	53 (36-76)	55 (34-73)	.87
Progressive disease at study entry, no.
No	14	19		15	7
Yes	28	43	.83	29	30	.13
Baseline performance status, no.
0	37	53		36	32
1	5	9	.78	8	5	.76
Pretreatment (chemotherapy), no.
No	17	20		22	18
Yes	25	42	.41	22	19	> .999
Metastatic sites, no.
1	17	34		22	22
2	13	21		14	15
3+	12	7	.04*	8	0	.06
Tumor sites, no.
Lung	4	20	.009*	12	7	.44
Liver	21	24	.31	20	10	.11
Bone	26	26	.07	19	14	.66
Other sites	24	23	.048*	19	19	.51
Estrogen receptors, no.
Absent	16	24		16	12
Present	23	32	> .999	26	21	> .999
Progesterone receptors, no.
Absent	22	27		19	16
Present	17	28	.53	21	15	.81
Ki67, no.
Less than 20%	14	18		9	14
20% or more	8	9	> .999	7	2	.11
Her-2/Neu, no.
0/+/++	24	27		17	18
+++	2	6	.45	4	2	.66
pT, no.
pT1	6	17		11	8
pT2	14	20		12	12
pT3-4	4	4	.17	4	1	.70
pN, no.
pNo	4	14		8	5
pN1-pN2	17	27	.25	21	14	> .999
Epidermal growth factor receptor at baseline, no.
Less than 52 fmol/mg	27	5		11	21
Greater than or equal to 52 fmol/mg	27	10	.38	20	22	.34
Median (range)	56 (38-71)	52 (39-64)	.07	52 (34-64)	55 (39-71)	.12

	CEC at baseline					CEC at 2 mo
	11/μL or less	More than 11/μL	P	11/μL or less	More than 11/μL	P
No. entered or eligible	42	62		44	37
Median age, y (range)	54 (32-78)	54 (34-78)	.71	53 (36-76)	55 (34-73)	.87
Progressive disease at study entry, no.
No	14	19		15	7
Yes	28	43	.83	29	30	.13
Baseline performance status, no.
0	37	53		36	32
1	5	9	.78	8	5	.76
Pretreatment (chemotherapy), no.
No	17	20		22	18
Yes	25	42	.41	22	19	> .999
Metastatic sites, no.
1	17	34		22	22
2	13	21		14	15
3+	12	7	.04*	8	0	.06
Tumor sites, no.
Lung	4	20	.009*	12	7	.44
Liver	21	24	.31	20	10	.11
Bone	26	26	.07	19	14	.66
Other sites	24	23	.048*	19	19	.51
Estrogen receptors, no.
Absent	16	24		16	12
Present	23	32	> .999	26	21	> .999
Progesterone receptors, no.
Absent	22	27		19	16
Present	17	28	.53	21	15	.81
Ki67, no.
Less than 20%	14	18		9	14
20% or more	8	9	> .999	7	2	.11
Her-2/Neu, no.
0/+/++	24	27		17	18
+++	2	6	.45	4	2	.66
pT, no.
pT1	6	17		11	8
pT2	14	20		12	12
pT3-4	4	4	.17	4	1	.70
pN, no.
pNo	4	14		8	5
pN1-pN2	17	27	.25	21	14	> .999
Epidermal growth factor receptor at baseline, no.
Less than 52 fmol/mg	27	5		11	21
Greater than or equal to 52 fmol/mg	27	10	.38	20	22	.34
Median (range)	56 (38-71)	52 (39-64)	.07	52 (34-64)	55 (39-71)	.12

pT and pN refer to the TNM_UICC classification on primary tumory regional nodes and metastases. The definition of characteristics of the disease is focused on features related to the primary tumor (T), to the regional lymph nodes—including those of the ipsilateral axilla, supraclavicular, and internal mammary sites (N)—and of distant metastases.

View Large

This Feature Is Available To Subscribers Only